Glosario

 

DM 2= Diabetes Mellitus Tipo 2

IR= Insulinorresistencia

HI= Hiperinsulinemia

IG= Intolerancia a la glucosa

HTA= Hipertensión arterial

DL= Dislipemia

RER= Retículo endoplásmico rugoso

GLUT= Transportador específico de glucosa

EGF= Factor de crecimiento epidérmico

PDGF= Factor de crecimiento derivado de las plaquetas

IRS 1= Sustrato del receptor de insulina

IGF 1= Factor de crecimiento insulinosímil

PI 3= Fosfoinositol 3 quinasa

NGF= Factor de crecimiento neural

MSA= Factor de crecimiento estimulante de la multiplicación

PAI 1= Inhibidor del activador del plasminógeno

OB-AV= Obesidad abdominovisceral

HHA= Hipotálamo hipófiso-adrenal

AGL= Ácidos grasos libres

TNF alfa= Factor de necrosis tumoral alfa

IMC= Índice de masa corporal

NPY= Neuropéptido Y

MSH= Hormona melanocito estimulante

GH= Somatotrofina

IGF BP 1= Proteína transportadora de IGF 1

SHBG= Proteína transportadora de esteroides sexuales

LH= Hormona luteinizante

AGNE= Ácidos grasos no esterificados

 

 

Bibliografía

 

1.     Litwak, L. y col. Síndrome Polimetabólico. Una Situación frecuente en la práctica diaria. RAEM. 1996, Vol. 33, N0 1: 4-18.

2.     Pierre – Jean Guillausseau. Diabetes Tipo II: Una Actualización. Groupe de Recherche.Servier.1999.

3.     Frechtel, G.D. Bases Fisiopatológicas y Moleculares de la diabetes tipo II. Seporata 1998. Química Montpellier S.A.

4.     Ellenberg, M. et al. Diabetes Mellitus. Theory and Practice, Third Edition 1996. Pag. 1 – 96.

5.     Lastreto, B. Mereshian, P. Páncreas. Endocrino. Fisiología Humana, tomo 1. Primera Edición 1998. Pag. 263 – 287.

6.     Kannel, W.B. La tensión arterial como factor de riesgo cardiovascular. Prevención y tratamiento. JAMA (ed. Arg.), vol. 6 No 2. 1997.

7.     Reaven, G.M et al. Hipertensión y Anomalías Metabólicas Asociadas. El Rol de la Resistencia a la Insulina y el Sistema Simpático – Suprarrenal. The New England Journal of Medicine. Vol. 334 No 6, 1996.

8.     Kannel, W.B et al. Diabetes and Cardiovascular. Risk Factors: The Framingham Study. Circulation, Vol 59, N0 1, 1997.

9.     Fuller, J.H. Hipertension and Diabetes. Epidemiologie Aspects as a Guide to Management. Journal of Cardiovascular Pharmacology. Vol 21 (Suppl. 2) 1993.

10.   Kannel, W>B. et al. The Epidemiology of Imparied glucose Tolerance and hipertension. American Heart Journal, Vol 121, N0 4, Part. 2, 1991.

11.   Stamler, J. et al. Diabetes, Other Risk Factors, and 12 –Yr. Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. Vol 16, No 2, 1993.

12.   Ferrannini, E. et al. Insulin Resístanse In Essential Hipertension. The New England journal of Medicine Vol 317, No 6, 1997.

13.   Screening for Type 2 Diabetes. Diabetes Care, vol 23, suppl. 1, 2000.

14.   Report of the Expert Committee on the Diagnosis and Classification of D.M. Diabetes Care, Vol. 23, Suppl. 1, 2000.

15.   Smoking and Diabetes. Diabetes Care, Vol. 23, No 1, 2000.

16.   Shaw, J.E. et al. Impared Fasting Glucose: How Low Should It go?. Diabetes Care, Vol. 23, No 1. 2000.

17.   Vegt, F. Et al. Similar 9 year. Mortality Risks and Reproducibility for the World Health Organization and American Diabetes Association Glucose Tolerance. Categories. Diabetes Care, Vol 23, No 1, 2000.

18.   Muggeo, M. et al Fasting Plasma Glucose Variability Predicts 10 Year Survival of Type 2. Diabetic Patients. Diabetes Care, Vol 23, No 1, 2000.

19.   Mac Gregor, A. S. et al. Role of Systolic Blood Pressure and Plasma Triglycerides in Diabetic Peripheral Arterial Discase. Diebates Care, Vol 22, No 3, 1999.

20.   Harris, M. I. Et al. Racial and Ethic Differences in Glicemic Control of Adults with Type 2 Diabetes. Diabetes Care, Vol 22, No 3, 1999.

21.   Lindahl, B. et al. Screening for impaired Glucose Tolerance. Diabetes Care, Vol 22, No 12, 1999.

22.   Yamamoto, M. et al. Impaired Diurnal Cardiac Autonomie Finction in Subjects with Type 2 Diabetes. Diabetes Care, Vol 22, No 12, 1999.

23.   Rosenbloom, A.L. et al.Emerging Epidemie of Type 2. Diabetes Youth. Diabetes Care. Vol 22 No 2, 1999.

24.   Doria, A. Et al. Phenotypie Characterictics of Early onset. Autosomal Dominant. Type 2 Diabetes Unlinked to Knows Maturity – Onset Diabetes of the young (MODY). Genes. Diabetes Care, Vol 22, No 2, 1999.

25.   Wareham, N.J. et al. Fasting Proinsulin Concentrations Predict the development of Type 2. Diabetes. Diabetes Care, Vol 22, No 2, 1999.

26.   Campagna, A.F. et al. HDl Colesterol Subfractions and Risk of Developing Type 2 Diabetes Among Pima Indians. Diabetes Care, Vol 22, No 2, 1999.

27.   Suematsu, Ch. et al. Impaired Fasting Glucose and the risk of Hipertension japanese men between the 1980 s and the 1990 s. Diabetes Care, Vol 22, No 2, 1999.

28.   Coutinho, M. et al. The Relationship between Glucose and Incident Cardiovascular Events. Diabetes Care, Vol 22, No 2, 1999.

29.   Chee Eng Tan. Et al. Prevalence of Diabetes and Ethnic Differences Cardiovascular Risk Factors. Diabetes Care, Vol 22, No 2. 1999.

30.   Naoyawatanabe. Et al. Elevated Remnant – Like Lipoprotein Particles In Impaired Glucose Tolerance and Type 2 Diabetic Patients. Diebetes Care, Vol 22, 1999.

31.   Meneilly, G.S et al. Metabolic Alterations in Midde – Aged and Elderly Obese Patients with Type 2 Diabetes. Diabetes Care, Vol 22, No 1, 1999.

32.   Kekalainen, P. et al. Hiperinsulinemia Cluster Predicts the Development of Type 2 Diabetes Independently of Family History of Diabetes. Diabetes Care, Vol 22, No 1, 1999.

33.   Wollensen, F. Et al. Peripheral Atherosclerosis and Serum Lipoprotein ( ) in Diabetes. Diabetes Care, Vol 22, No 1, 1999.

34.   Bruno, G. et al. Clinical, Inmunological, and Genetic Heterogenecity of Diabetes in Italian Population. Based Cohort of Lean. Newly Diagnosed Patients Aged 30 – 54 years. Diabetes Care, Vol 22, No 1, 1999.

35.   Bjornholt, J. V. et al. Fasting Blood Glucose: Underestimated Risk Factor for Cardiovascular Death. Diabetes Care, Vol 22, No 1, 1999.

36.   Vanzetto, G. at al. Predictions of Cardiovascular Events in Clinically Seleted High – Risk NIDDM Patients. Diabetes Care, Vol 22, No 1, 1999.

37.   Haffner, S.M. et al. Insulin Sensivity in Subjects with Type 2 Diabetes. Diabetes Care, Vol 22, No 4, 1999.

38.   Elbein, S.C. et al. Reduced B – Cell. Compensation to the Insulin Resistance Associated with Obesity in Members of Caucasion Familial Type 2 Diabetic Kindreds. Diabetes Care, Vol 23, No 2, 2000.

39.   Hawa, M.I. et al. Antibodies to IA. 2 and GAD 65 in Type 1 and Type 2 Diabetes. Diabetes Care, Vol 23, No 2, 2000.

40.   MOOY, J. M. et al. Major Stressful Life Events in Relation to Prevalence of Undetected Type 2 Diabetes. Diabetes Care, Vol 23, No 2, 2000.

41.   Yeni – Komshian, H. et al. Relationship Between Several Surrogate Estimates of Insulin – Mediated Glucose Disposal in 490 Healthy Nondiabetic Volunteers. Diabetes Care, Vol 23, No 2, 2000.

42.   American Diabetes Association. Standards of Medical Care for Patients with Diabetes Mellitus. Diabetes Care, Vol 23, Suppl. 1, 2000.

43.   American Diabetes Association. Management of Dyslipidemia in adults with Diabetes. Diabetes Care, Vol 23, Suppl. 1, 2000.

44.   Su – Chi – Li et al. Cardiovascular Risk Profile in Individual with Borderline Glicemia. Diabetes Care, Vol 23, No 3, 2000.

45.   Foss, C. H. et al. Normal Blood Presure and Preserved Diurnal Variation in offspring of Type 2 Diabetic Characterized by Features of the Metabolic Sindrome. Diabetes Care, Vol 23, No 3, 2000.

46.   Stumvoll, M. et al. Use of the Oral Glucose Tolerance Test to Assess Insulin Release and Insulin Sensitivity. Diabetes Care, Vol 23, No 3, 2000.

47.   Revision Internacional Roche. Obesidad: Una Enfermedad no reconocida. Complicaciones y Manejo Actual. 1999.

48.   Temple, R. Et al. Medición de la Secreción de Insulina en la diabetes de Tipo II, problemas y dificultades. Diabet. Med. 9:503 – 512. 1992.

49.   Francesconi, M. et al. El paciente diabético con sobrepeso. Diabetoghaphia. Pub. Med. Internacional. Ed. 14. 1999.

50.   Davies, M.J. et al. Diabetes y Secreción de Insulina. Diabet. Med. 1993. 10:305-312.

51.   Giugliano, D. Et al. Diabetes y Complicaciones vasculares. Metabolism. 1993. 44:363-368.

52.   Ferrannini, E. Insulin Resistance versus Insulin deficiency in Noninsulin – Dependent. Diabetes Mellitus: Problems and prospects. Endocrine Reviews 19 (4): 477 – 490. 1998

53.   Scaglia, H. Resistencia a la Insulina Aspectos Bioquímicos y Moleculares. RAEM, 2000. Vol. 37. No 4

54.   Sinay, I. Resistencia a la Insulina. Aspectos Clínicos. RAEM. 2000. Vol 37. No 4

55.   Sinay, I. Resistencia a la Insulina. Diagnóstico. RAEM. 2000. Vol 37. No 4

56.   Costa Gil, J.E. Resistencia a la Insulina. Tratamiento. RAEM. 2000. Vol 37. No 4

57.   Kennedy, A. Et. Al. The Metabolic Significance of Leptin in Humans: Gender – Based Differences in Relationship to Adiposity, Insulin Sensitivity, and Energy Expenditure. Journal of Clinical Endocrinology and Metabolism. 1997

58.   MC Neely, M.J. et. Al. Asociation Between Baseline Plasma Leptin Levels and Subsequent Development of Diabetes in Japanese Americans Diabetes Care 22:65 – 70, 1999.

59.   Rossetti, L. Simposio. Obesidad. Forum, No 35. 1997.

60.   Fox, C. Plasma leptin Concentrations in Pima Indians Living in Drastically Different Environments. Diabetes Care 22:413 – 417. 1999

61.   Contreras. P Manual de Aspectos no reproductivos en Endocrinología Ginecológica – Insulinorresistencia en Endocrinología Ginecológica. Cap. 2 pág. 91.

62.   Bonora, E Homeostasis Model Assessment. Closely Mirrors the glucose Clamp Technique in the Assessment of Insulin Sensitivyty.